Hematology & oncology

Click on each therapeutic area to learn more.

Myelofibrosis (MF)

MF is a rare hematologic cancer characterized by scarring of the bone marrow, as well as disruption of the normal production of blood cells. Approximately 20,000 people in the United States have been diagnosed with MF.

MF publications

The publications on this page are sponsored by Sobi and pertain to select Sobi products in this disease area. This page is not intended to serve as a comprehensive overview of all publications in this disease area. Publications may include information for which the product is not approved and/or that is inconsistent with the product uses described in the Prescribing Information. Sobi does not suggest or recommend the use of Sobi products in any manner other than as described in the Prescribing Information.

Pacritinib Versus Best Available Therapy for the Treatment of Myelofibrosis Irrespective of Baseline Cytopenias (PERSIST-1): An International, Randomised, Phase 3 Trial
Lancet Haematology, May 2017
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial
JAMA Oncology, May 2018
Determining the Recommended Dose of Pacritinib: Results From the PAC203 Dose-Finding Trial in Advanced Myelofibrosis
Blood Advances, November 2020
Early Anemia Response in Patients With Myelofibrosis Treated With Pacritinib in Real-World Clinical Settings
Blood, November 2024
Hematologic Improvement Experienced by Pacritinib-Treated Patients With Myelofibrosis in Real-World Clinical Settings
Blood, November 2024
Real-World Effectiveness of Pacritinib in Patients With Myelofibrosis Who Have Thrombocytopenia and Anemia
Blood, November 2024

Immune thrombocytopenia (ITP)

Immune thrombocytopenia (ITP) is a rare autoimmune disease affecting platelet production and characterized by bleeding, bruising, and fatigue. In the United States, approximately 9 to 10 people in every 100,000 have ITP.

ITP publications

The publications on this page are sponsored by Sobi and pertain to select Sobi products in this disease area. This page is not intended to serve as a comprehensive overview of all publications in this disease area. Publications may include information for which the product is not approved and/or that is inconsistent with the product uses described in the Prescribing Information. Sobi does not suggest or recommend the use of Sobi products in any manner other than as described in the Prescribing Information.

Phase 3 Randomised Study of Avatrombopag, a Novel Thrombopoietin Receptor Agonist for the Treatment of Chronic Immune Thrombocytopenia
British Journal of Haematology, September 2018
Efficacy and Safety of Avatrombopag in Japanese Adults With Chronic Immune Thrombocytopenia: Open-Label, Phase 3 Study
Blood, November 2024
Use of Avatrombopag in Patients With Immune Thrombocytopenia: Interim Analysis of the Phase 4 ADOPT Study
Blood, November 2024
Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch From Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-hoc Analyses From a Prospective Phase 4 Study
Blood, November 2024
Long-Term Response Rates in Patients With Chronic Immune Thrombocytopenia Treated With Avatrombopag: Additional Analyses From a Phase 3 Study and Its Extension Phase
Blood, November 2024
Platelet Response to Avatrombopag in Patients With Chronic Immune Thrombocytopenia: Additional Analyses from a Phase 3 Study and Its Extension
Blood, November 2024